1.56

6.12% 0.09

After Hours: 1.55 -0.01 -0.64%

Akebia Therapeutics Inc (AKBA)

Overview News Price History Option Chain Financials Discussions Forecast

Akebia Therapeutics Inc stock is traded at $1.56, with a volume of 2.26M. It is up +6.12% in the last 24 hours and up +6.85% over the past month. Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Previous Close:

$1.47

Open:

$1.48

24h Volume:

2.26M

Relative Volume:

0.73

Market Cap:

$417.89M

Revenue:

$236.20M

Net Income/Loss:

$-5.35M

P/E Ratio:

-87.15

EPS:

-0.0179

Net Cash Flow:

$67.70M

1W Performance:

+13.04%

1M Performance:

+6.85%

6M Performance:

-44.09%

1Y Performance:

-14.75%

1-Day Range:

$1.47

$1.56

1-Week Range:

$1.38

$1.56

52-Week Range:

$1.14

$4.0787

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name

Akebia Therapeutics Inc

Sector

Healthcare (1110)

Industry

Drug Manufacturers - Specialty & Generic (83)

Phone

617-871-2098

Address

245 FIRST STREET, CAMBRIDGE, MA

Employee

194

Twitter

@akebiatx

Next Earnings Date

2024-11-07

Latest SEC Filings

AKBA's Discussions on Twitter

Compare AKBA vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKBA Akebia Therapeutics Inc	1.56	375.03M	236.20M	-5.35M	67.70M	-0.0179
TAK Takeda Pharmaceutical Co Adr	17.85	57.12B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	121.11	49.56B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.70	43.86B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.77	35.89B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	578.54	25.06B	3.18B	1.33B	1.04B	27.90

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-04-25	Resumed	H.C. Wainwright	Buy
Apr-28-25	Initiated	Leerink Partners	Outperform
Apr-01-25	Initiated	Jefferies	Buy
Nov-29-23	Resumed	BTIG Research	Buy
Aug-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
May-31-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-31-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-22	Downgrade	Mizuho	Buy → Neutral
Mar-31-22	Downgrade	Needham	Buy → Hold
Mar-31-22	Downgrade	Piper Sandler	Overweight → Neutral
Mar-08-21	Initiated	Cantor Fitzgerald	Overweight
Jan-29-21	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-19	Reiterated	Needham	Buy
Aug-06-19	Reiterated	H.C. Wainwright	Buy
Jul-11-19	Reiterated	H.C. Wainwright	Buy
May-02-19	Initiated	JP Morgan	Overweight
Mar-20-19	Initiated	Citigroup	Neutral
Sep-07-18	Resumed	Morgan Stanley	Equal-Weight
Aug-10-18	Reiterated	Needham	Buy
Jun-06-18	Reiterated	H.C. Wainwright	Buy
Dec-19-17	Initiated	Piper Jaffray	Overweight
Dec-07-17	Initiated	BTIG Research	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Sector Perform
Jul-10-17	Reiterated	H.C. Wainwright	Buy
Apr-27-17	Reiterated	H.C. Wainwright	Buy
Apr-27-17	Reiterated	Needham	Buy
Dec-27-16	Reiterated	H.C. Wainwright	Buy
Dec-20-16	Reiterated	JMP Securities	Mkt Outperform
Nov-15-16	Initiated	Aegis Capital	Buy
Sep-29-16	Initiated	Brean Capital	Buy
Mar-16-16	Reiterated	Needham	Buy
Jan-21-16	Initiated	Credit Suisse	Neutral

View All

Akebia Therapeutics Inc Stock (AKBA) Latest News

Apr 14, 2026

H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - MSN

Apr 14, 2026

Leerink reiterates Akebia stock rating on regulatory precedent By Investing.com - Investing.com Australia

Apr 14, 2026

Apr 13, 2026

Akebia (AKBA) Initiates Phase 1 Trial for AKB-9090 Targeting Kid - GuruFocus

Apr 13, 2026

Akebia doses first patients in Phase 1 trial of AKB-9090 - Investing.com Canada

Apr 13, 2026

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 - The Manila Times

Apr 13, 2026

Akebia Therapeutics Leads The Pack Of 3 Promising Penny Stocks - Yahoo Finance

Apr 13, 2026

Akebia starts human testing of drug for kidney injury after heart surgery - Stock Titan

Apr 13, 2026

Profit Review: Is Akebia Therapeutics Inc attractive for institutional investorsGDP Growth & Momentum Based Trading Ideas - baoquankhu1.vn

Apr 13, 2026

Apr 09, 2026

Akebia Therapeutics (NASDAQ:AKBA) Rating Increased to Hold at Zacks Research - MarketBeat

Apr 09, 2026

Apr 08, 2026

Sectors Review: Is Akebia Therapeutics Inc stock trending bullishWeekly Risk Report & Detailed Earnings Play Strategies - baoquankhu1.vn

Apr 08, 2026

Block Trades: What is the next catalyst for Akebia Therapeutics IncQuarterly Profit Review & Consistent Growth Stock Picks - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium - marketscreener.com

Apr 07, 2026

BTIG Research Reaffirms "Buy" Rating for Akebia Therapeutics (NASDAQ:AKBA) - MarketBeat

Apr 07, 2026

Akebia executives head to New York for Apr. 14 biotech investor meetings - Stock Titan

Apr 07, 2026

BTIG Reiterates Buy Rating on AKBA with $4.00 Price Target | AKB - GuruFocus

Apr 07, 2026

H.C. Wainwright Keeps Their Buy Rating on Akebia Therapeutics (AKBA) - The Globe and Mail

Apr 07, 2026

Sell Signal: Does Akebia Therapeutics Inc offer margin of safetyMarket Trend Review & Smart Allocation Stock Tips - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4 - Moomoo

Apr 06, 2026

Fed Meeting: Is Akebia Therapeutics Incs ROIC above industry average2026 Trade Ideas & Safe Entry Zone Tips - baoquankhu1.vn

Apr 06, 2026